Login to Your Account

Other News To Note

Wednesday, March 27, 2013
• BioDelivery Sciences International Inc. (BDSI), of Raleigh, N.C., signed a worldwide licensing agreement with privately held Arcion Therapeutics Inc., of Baltimore, in which BDSI will develop and commercialize topical clonidine gel (formerly ARC4558) for the treatment of painful diabetic neuropathy and potentially other indications.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription